Nuvation Bio, Inc. Class A (NUVB)

Over the past six months, Nuvation Bio's stock has experienced a significant increase of 135.54%. Key events include the Q3 2025 earnings report with an EPS of -$0.16 and revenue of $13.12 million, clinical momentum with safusidenib, insider selling with a net value of -$5,634,615.58, preliminary Q4 and full-year 2025 financial results, a licensing agreement with Eisai for taletrectinib, presentation at the J.P. Morgan Healthcare Conference, and publication of safusidenib Phase 2 study results.

As a biopharmaceutical company focused on developing oncology treatments, the demand for Nuvation Bio's products and services is primarily driven by medical need and clinical outcomes rather than seasonal factors. Therefore, there is no significant demand seasonality for Nuvation Bio's products and services.

Nuvation Bio, Inc. is a global biopharmaceutical company focused on oncology, developing novel therapeutic candidates to address unmet needs. Their portfolio includes clinical-stage products like taletrectinib, safusidenib, NUV-868, and NUV-1511, targeting difficult-to-treat cancers. The company aims to improve patient outcomes by overcoming drug resistance, enhancing efficacy, reducing side effects, and preserving quality of life.

Nuvation Bio is a global biopharmaceutical company with offices in New York, San Francisco, Boston, and Shanghai.

Nuvation Bio holds a positive brand reputation among analysts, with a consensus rating of "Moderate Buy" and an average rating score of 2.83. The company also scored higher than 78% of companies evaluated by MarketBeat, ranking 242nd out of 872 stocks in the medical sector. Over the past year, NUVB exceeded the US Pharmaceuticals industry and the US Market.

Nuvation Bio's ownership is a mix of institutional, retail, and individual investors. Approximately 26.07% of the company's stock is owned by Institutional Investors, 17.60% by Insiders, and 56.33% by Public Companies and Individual Investors. Major institutional shareholders include Fmr Llc, Decheng Capital LLC, BlackRock, Inc., and Vanguard Group Inc.